Yaser ALGAIDI 医师
医学博士, (Medical student)
其他作者: Retaj Calacattawi 1, Mohammed Alshahrani 2, Maryam Aleid 3, Fatimah Aleid 3, Khalid Basamih 4, Ghada Alsugair 5, Raghad Alqahtani 6, Noor AlKhabbaz 3, Yaser Algaidi 7, Latifa Alrakayan 3, Abdulaziz Almohanna 8, Afnan Madkhali 9, Shaima Aljohani 10, Naif A
Tranexamic acid as a therapeutic option for melasma management: Meta-analysis and systematic review of randomized controlled trials
Objectives: To assess the efficacy of tranexamic acid (TXA) in treating melasma and evaluate its associated adverse effects compared to other melasma treatments.
Introduction: Melasma is a challenging condition to treat. Tranexamic acid (TXA) has emerged as a promising therapy, but its effectiveness and safety compared to other treatments need comprehensive evaluation.
Materials / method: A systematic review and meta-analysis were conducted on 22 RCTs (n=1280 patients) following PROSPERO and PRISMA guidelines. Databases searched included PubMed, Scopus, Cochrane, and Embase. Inclusion criteria focused on full-text English RCTs with clear outcome measures on TXA in melasma. Data were analyzed using RevMan software, with heterogeneity assessed using I² statistics and forest plots.
Results: TXA was administered orally, topically, or via injection. Significant reductions were observed in MASI (mean difference: -4.32) and mMASI scores. Oral TXA was most effective, followed by injections and topical treatments. Adverse effects included gastrointestinal issues and skin irritation.
Conclusion: TXA is effective in reducing melasma severity, but further research is needed to optimize administration methods and address treatment heterogeneity.
